Skip to content
2000
Volume 22, Issue 1
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Background

Rheumatoid Arthritis (RA) is a chronic autoimmune inflammatory disease that affects synovial membranes, leading to relentless progressive joint damage. This pathological process is regulated by transcription factors, such as NF-κB, STAT3, TGF-β, WNT, p38 MAPK, mTOR, AP-1, TLR-4, SOCS-4, YY-1, IRF, and FGF-20, which enhance the production of matrix-degrading enzymes and proinflammatory cytokines. Dysregulation of these transcription factors amplifies inflammation and accelerates joint damage, making them potential therapeutic targets.

Objectives

The purpose of this review was to summarize the role of transcription factors in RA and the onset of synovitis and identify potential therapeutic targets to mitigate joint damage.

Methodology

A comprehensive search of electronic databases (PubMed, Google Scholar, and Web of Science) was conducted. Additionally, searches of government health ministries and websites were performed to retrieve relevant information. Records available until March 12, 2024, were considered. Screening (primary and secondary) of the records and data extraction from eligible studies were carried out.

Results

Synovitis sustains a proinflammatory environment mediated by dysregulated transcription factors, as mentioned earlier. These transcription factors promote the production of inflammatory cytokines and matrix-degrading enzymes, leading to progressive joint destruction. Therefore, targeting these transcription factors or their upstream regulators may offer promising therapeutic interventions for RA.

Conclusion

The pathogenesis of RA centers on transcription factors responsible for the inflammatory and destructive processes in synovitis. These molecules are ideal targets for developing novel treatments. Further elucidation of their complex molecular interactions and advancements in personalized therapies for RA patients is necessary.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971346656250403051144
2025-04-15
2026-03-02

  • From This Site

    /content/journals/crr/10.2174/0115733971346656250403051144
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FiresteinG.S. Evolving concepts of rheumatoid arthritis.Nature2003423693735636110.1038/nature0166112748655
     [Google Scholar]
  2. PalR. ChaudharyM.J. TiwariP.C. NathR. PantK.K. Pharmacological and biochemical studies on protective effects of mangiferin and its interaction with nitric oxide (NO) modulators in adjuvant-induced changes in arthritic parameters, inflammatory, and oxidative biomarkers in rats.Inflammopharmacology20188050710.1007/s10787‑018‑0507‑829934863
     [Google Scholar]
  3. PalR. ChaudharyM.J. TiwariP.C. BabuS. PantK.K. Protective role of theophylline and their interaction with nitric oxide (NO) in adjuvant-induced rheumatoid arthritis in rats.Int. Immunopharmacol.201529285486210.1016/j.intimp.2015.08.03126349791
     [Google Scholar]
  4. PalR. ChaudharyM.J. TiwariP.C. NathR. BabuS. PantK.K. Pharmacological studies on the anti-inflammatory and immunomodulatory role of pentoxifylline and its interaction with nitric oxide (NO) in experimental arthritis in rats.Inflammopharmacology201624522123110.1007/s10787‑016‑0281‑427671331
     [Google Scholar]
  5. SmolenJ.S. LandewéR.B.M. van der HeijdeD. Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: No utopia for patients in low/middle-income countries?' by Misra et al. Ann. Rheum. Dis.20177611e4810.1136/annrheumdis‑2017‑21145528478402
     [Google Scholar]
  6. BottiniN. FiresteinG.S. Epigenetics in rheumatoid arthritis: A primer for rheumatologists.Curr. Rheumatol. Rep.2013151137210.1007/s11926‑013‑0372‑924072602
     [Google Scholar]
  7. McInnesI.B. SchettG. Cytokines in the pathogenesis of rheumatoid arthritis.Nat. Rev. Immunol.20077642944210.1038/nri209417525752
     [Google Scholar]
  8. BonelliM. DalwigkK. PlatzerA. Olmos CalvoI. HayerS. NiederreiterB. HolinkaJ. SeveldaF. PapT. SteinerG. Superti-FurgaG. SmolenJ.S. KienerH.P. KaronitschT. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes.Exp. Mol. Med.201951711110.1038/s12276‑019‑0267‑631285419
     [Google Scholar]
  9. DennisG.Jr HolwegC.T.J. KummerfeldS.K. ChoyD.F. SetiadiA.F. HackneyJ.A. HavertyP.M. GilbertH. LinW.Y. DiehlL. FischerS. SongA. MusselmanD. KlearmanM. GabayC. KavanaughA. EndresJ. FoxD.A. MartinF. TownsendM.J. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.Arthritis Res. Ther.2014162R9010.1186/ar455525167216
     [Google Scholar]
  10. ScottD.L. WolfeF. HuizingaT.W.J. Rheumatoid arthritis.Lancet201037697461094110810.1016/S0140‑6736(10)60826‑420870100
     [Google Scholar]
  11. BartokB. FiresteinG.S. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis.Immunol. Rev.2010233123325510.1111/j.0105‑2896.2009.00859.x20193003
     [Google Scholar]
  12. SzekaneczZ. SzekaneczÉ. BakóG. ShoenfeldY. Malignancies in autoimmune rheumatic diseases - a mini-review.Gerontology201157131010.1159/00031463420453490
     [Google Scholar]
  13. ManzoA. BombardieriM. HumbyF. PitzalisC. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: From inflammation to autoimmunity and tissue damage/remodeling.Immunol. Rev.2010233126728510.1111/j.0105‑2896.2009.00861.x20193005
     [Google Scholar]
  14. FiresteinG.S. McInnesI.B. Immunopathogenesis of rheumatoid arthritis.Immunity201746218319610.1016/j.immuni.2017.02.00628228278
     [Google Scholar]
  15. AloisiF. Pujol-BorrellR. Lymphoid neogenesis in chronic inflammatory diseases.Nat. Rev. Immunol.20066320521710.1038/nri178616498451
     [Google Scholar]
  16. TakemuraS. BraunA. CrowsonC. KurtinP.J. CofieldR.H. O’FallonW.M. GoronzyJ.J. WeyandC.M. Lymphoid neogenesis in rheumatoid synovitis.J. Immunol.200116721072108010.4049/jimmunol.167.2.107211441118
     [Google Scholar]
  17. CheonH. YuS.J. YooD.H. ChaeI.J. SongG.G. SohnJ. Increased expression of pro-inflammatory cytokines and metalloproteinase-1 by TGF-β 1 in synovial fibroblasts from rheumatoid arthritis and normal individuals.Clin. Exp. Immunol.2002127354755210.1046/j.1365‑2249.2002.01785.x11966774
     [Google Scholar]
  18. O’SheaJ.J. PaulW.E. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells.Science201032759691098110210.1126/science.117833420185720
     [Google Scholar]
  19. GhoshS. MayM.J. KoppE.B. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses.Annu. Rev. Immunol.199816122526010.1146/annurev.immunol.16.1.2259597130
     [Google Scholar]
  20. TakedaK. ClausenB.E. KaishoT. TsujimuraT. TeradaN. FörsterI. AkiraS. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils.Immunity1999101394910.1016/S1074‑7613(00)80005‑910023769
     [Google Scholar]
  21. HernándezD.A.Z. ChagollánM.G. ZunoG.A.S. ArellanoS.G. BelloJ.H. PalmaL.A.H. Expression of transcriptional factors of T helper differentiation (T-bet, GATA-3, RORγt, and FOXP3), MIF receptors (CD44, CD74, CXCR2, 4, 7), and Th1, Th2, and Th17 cytokines in PBMC from control subjects and rheumatoid arthritis patients.Curr. Mol. Med.20232491169118210.2174/011566524026097623092509533037807647
     [Google Scholar]
  22. ZhouL.F. ZengW. SunL.C. WangY. JiangF. LiX. ZhengY. WuG.M. IKKε aggravates inflammatory response via activation of NF-κB in rheumatoid arthritis.Eur. Rev. Med. Pharmacol. Sci.20182272126213329687872
     [Google Scholar]
  23. Roman-BlasJ.A. JimenezS.A. NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis.Osteoarthritis Cartilage200614983984810.1016/j.joca.2006.04.00816730463
     [Google Scholar]
  24. PalR. TiwariP.C. NathR. BabuS. PantK.K. Phosphodiesterase (PDE) inhibitors and their interaction with nitric oxide (NO) modulators in adjuvant-induced rheumatoid arthritis.FASEB J.201630S1lb55610.1096/fasebj.30.1_supplement.lb556
     [Google Scholar]
  25. PalR. TiwariP.C. NathR. PantK.K. Role of cAMP/cGMP-PDE inhibitors and their interactions with L-arginine & L-NAME in adjuvant induced rheumatoid arthritis in rats.Proceedings for annual meeting of the japanese pharmacological society2018, pp. 5-27.10.1254/jpssuppl.WCP2018.0_PO2‑5‑27
     [Google Scholar]
  26. PalR. ChaudharyM.J. TiwariP.C. NathR. PantK.K. Pharmacological and biochemical studies on protective effects of mangiferin and its interaction with nitric oxide (NO) modulators in adjuvant-induced changes in arthritic parameters, inflammatory, and oxidative biomarkers in rats.Inflammopharmacology201927229129910.1007/s10787‑018‑0507‑829934863
     [Google Scholar]
  27. ChenZ. LinF. GaoY. LiZ. ZhangJ. XingY. DengZ. YaoZ. TsunA. LiB. FOXP3 and RORγt: Transcriptional regulation of Treg and Th17.Int. Immunopharmacol.201111553654210.1016/j.intimp.2010.11.00821081189
     [Google Scholar]
  28. KondoN. KurodaT. KobayashiD. Cytokine networks in the pathogenesis of rheumatoid arthritis.Int. J. Mol. Sci.202122201092210.3390/ijms22201092234681582
     [Google Scholar]
  29. ZhangJ. LiuH. ChenY. LiuH. ZhangS. YinG. XieQ. Augmenting regulatory T cells: New therapeutic strategy for rheumatoid arthritis.Front. Immunol.202415131291910.3389/fimmu.2024.131291938322264
     [Google Scholar]
  30. LuoP. WangP. XuJ. HouW. XuP. XuK. LiuL. Immunomodulatory role of T helper cells in rheumatoid arthritis.Bone Joint Res.202211742643810.1302/2046‑3758.117.BJR‑2021‑0594.R135775145
     [Google Scholar]
  31. IlchovskaD.D. BarrowD.M. An overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand rankl and related nutritional interventions.Autoimmun. Rev.202120210274110.1016/j.autrev.2020.10274133340772
     [Google Scholar]
  32. HandelM.L. McmorrowL.B. GravalleseE.M. Nuclear factor– k B in rheumatoid synovium. Localization of P50 and P65.Arthritis Rheum.199538121762177010.1002/art.17803812098849348
     [Google Scholar]
  33. SerasanambatiM. ChilakapatiS.R. Function of nuclear factor kappa B (NF-kB) in human diseases-a review.Sou. Ind. J. Biolog. Sci.20162436838710.22205/sijbs/2016/v2/i4/103443
     [Google Scholar]
  34. UchidaT. AkasakiY. SueishiT. KurakazuI. ToyaM. KuwaharaM. HiroseR. HyodoY. TsushimaH. LotzM.K. NakashimaY. Promotion of knee cartilage degradation by IκB kinase ε in the pathogenesis of osteoarthritis in human and murine models.Arthr. Rheumatol.202375693794910.1002/art.4242136530063
     [Google Scholar]
  35. AkhterS. IrfanH.M. Alamgeer JahanS. ShahzadM. LatifM.B. Nerolidol: A potential approach in rheumatoid arthritis through reduction of TNF-α, IL-1β, IL-6, NF-kB, COX-2 and antioxidant effect in CFA-induced arthritic model.Inflammopharmacology202230253754810.1007/s10787‑022‑00930‑235212850
     [Google Scholar]
  36. HaydenM.S. GhoshS. Shared principles in NF-kappaB signaling.Cell2008132334436210.1016/j.cell.2008.01.02018267068
     [Google Scholar]
  37. KarinM. Ben-NeriahY. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity.Annu. Rev. Immunol.200018162166310.1146/annurev.immunol.18.1.62110837071
     [Google Scholar]
  38. LiuT. ZhangL. JooD. SunS.C. NF-κB signaling in inflammation.Signal Transduct. Target. Ther.2017211702310.1038/sigtrans.2017.2329158945
     [Google Scholar]
  39. DavenportA.P. ScullyC.C.G. de GraafC. BrownA.J.H. MaguireJ.J. Advances in therapeutic peptides targeting G protein-coupled receptors.Nat. Rev. Drug. Discov.202019638941310.1038/s41573‑020‑0062‑z32494050
     [Google Scholar]
  40. IsomäkiP. JunttilaI. VidqvistK.L. KorpelaM. SilvennoinenO. The activity of JAK-STAT pathways in rheumatoid arthritis: Constitutive activation of STAT3 correlates with interleukin 6 levels.Rheumatology (Oxford)20155461103111310.1093/rheumatology/keu43025406356
     [Google Scholar]
  41. WalkerJ.G. SmithM.D. The Jak-STAT pathway in rheumatoid arthritis.J. Rheumatol.20053291650165316142855
     [Google Scholar]
  42. KrauseA. ScalettaN. JiJ.D. IvashkivL.B. Rheumatoid arthritis synoviocyte survival is dependent on Stat3.J. Immunol.2002169116610661610.4049/jimmunol.169.11.661012444174
     [Google Scholar]
  43. GarbersC. Aparicio-SiegmundS. Rose-JohnS. The IL-6/gp130/STAT3 signaling axis: Recent advances towards specific inhibition.Curr. Opin. Immunol.201534758210.1016/j.coi.2015.02.00825749511
     [Google Scholar]
  44. MoriT. MiyamotoT. YoshidaH. AsakawaM. KawasumiM. KobayashiT. MoriokaH. ChibaK. ToyamaY. YoshimuraA. IL-1 and TNF -initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.Int. Immunol.2011231170171210.1093/intimm/dxr07721937456
     [Google Scholar]
  45. OikeT. SatoY. KobayashiT. MiyamotoK. NakamuraS. KanekoY. Stat3 as a potential therapeutic target for rheumatoid arthritis.Sci. Rep.2017711096510.1038/s41598‑017‑11233‑w
     [Google Scholar]
  46. O’SheaJ.J. PlengeR. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.Immunity201236454255010.1016/j.immuni.2012.03.01422520847
     [Google Scholar]
  47. DarnellJ.E.Jr STATs and gene regulation.Science199727753321630163510.1126/science.277.5332.16309287210
     [Google Scholar]
  48. Gonzalo-GilE. Galindo-IzquierdoM. Role of transforming growth factor-beta (TGF) beta in the physiopathology of rheumatoid arthritis.Reumatol. Clin.201410317417910.1016/j.reuma.2014.01.00924685296
     [Google Scholar]
  49. SzekaneczZ. HainesG.K. HarlowL.A. ShahM.R. FongT.W. FuR. LinS.J.W. RayanG. KochA.E. Increased synovial expression of transforming growth factor (TGF)-β receptor endoglin and TGF-β 1 in rheumatoid arthritis: Possible interactions in the pathogenesis of the disease.Clin. Immunol. Immunopathol.199576218719410.1006/clin.1995.11147614737
     [Google Scholar]
  50. PeresR.S. DonateP.B. TalbotJ. CecilioN.T. LoboP.R. MachadoC.C. LimaK.W.A. OliveiraR.D. CarregaroV. NakayaH.I. CunhaT.M. Alves-FilhoJ.C. LiewF.Y. Louzada-JuniorP. CunhaF.Q. TGF-β signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis.J. Autoimmun.201890495810.1016/j.jaut.2018.01.00429426578
     [Google Scholar]
  51. LoriesR.J. CorrM. LaneN.E. To Wnt or not to Wnt: The bone and joint health dilemma.Nat. Rev. Rheumatol.20139632833910.1038/nrrheum.2013.2523459013
     [Google Scholar]
  52. DaoussisD. AndonopoulosA.P. LiossisS-N.C. Wnt pathway and IL-17: Novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.Semin. Arthri. Rheum.201039536938310.1016/j.semarthrit.2008.10.00819095294
     [Google Scholar]
  53. SenM. Wnt signalling in rheumatoid arthritis.Rheumatology (Oxford)200544670871310.1093/rheumatology/keh55315705634
     [Google Scholar]
  54. RabeloF.S. da MotaL.M.H. LimaR.A.C. LimaF.A.C. BarraG.B. de CarvalhoJ.F. AmatoA.A. The Wnt signaling pathway and rheumatoid arthritis.Autoimmun. Rev.20109420721010.1016/j.autrev.2009.08.00319683077
     [Google Scholar]
  55. TakahashiN. MaedaK. IshiharaA. UeharaS. KobayashiY. Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals.Front. Biosci.2011161213010.2741/367321196156
     [Google Scholar]
  56. MiaoC. YangY. HeX. LiX. HuangC. HuangY. ZhangL. LvX.W. JinY. LiJ. Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling.Cell. Signal.201325102069207810.1016/j.cellsig.2013.04.00223602936
     [Google Scholar]
  57. XiaoC.Y. PanY.F. GuoX.H. WuY.Q. GuJ.R. CaiD.Z. Expression of β-catenin in rheumatoid arthritis fibroblast-like synoviocytes.Scand. J. Rheumatol.2011401263310.3109/03009742.2010.48676720840015
     [Google Scholar]
  58. HayatR. ManzoorM. HussainA. Wnt signaling pathway: A comprehensive review.Cell Biol. Int.202246686387710.1002/cbin.1179735297539
     [Google Scholar]
  59. LiangJ.J. LiH.R. ChenY. ZhouZ. ShiY.Q. ZhangL.L. XinL. ZhaoD.B. ZNRF3 regulates collagen-induced arthritis through NF-kB and Wnt pathways.Inflammation20204331077108710.1007/s10753‑020‑01193‑132125593
     [Google Scholar]
  60. WestraJ. LimburgP.C. p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis.Mini Rev. Med. Chem.20066886787410.2174/13895570677793498216918493
     [Google Scholar]
  61. SchettG. ZwerinaJ. FiresteinG. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis.Ann. Rheum. Dis.200867790991610.1136/ard.2007.07427817827184
     [Google Scholar]
  62. SonY. CheongY.-K. KimN.-H. ChungH.-T. KangD.G. PaeH.-O. Mitogen-activated protein kinases and reactive oxygen species: How can ROS activate MAPK pathways?J. Sig. Transduct.2011201179263910.1155/2011/79263921637379
     [Google Scholar]
  63. KimE.K. ChoiE.J. Pathological roles of MAPK signaling pathways in human diseases.Biochim. Biophys. Acta Mol. Basis Dis.20101802439640510.1016/j.bbadis.2009.12.009
     [Google Scholar]
  64. CuendaA. RousseauS. p38 MAP-Kinases pathway regulation, function and role in human diseases.Biochim. Biophys. Acta Mol. Cell Res.2007177381358137510.1016/j.bbamcr.2007.03.01017481747
     [Google Scholar]
  65. CuendaA. LizcanoJ.M. LozanoJ. Mitogen activated protein kinases.Front. Medi.201798010.3389/978‑2‑88945‑339‑9
     [Google Scholar]
  66. SutoT. KaronitschT. The immunobiology of mTOR in autoimmunity.J. Autoimmun.202011010237310.1016/j.jaut.2019.10237331831256
     [Google Scholar]
  67. PerlA. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Nat. Rev. Rheumatol.201612316918210.1038/nrrheum.2015.17226698023
     [Google Scholar]
  68. MalemudC.J. The PI3K/Akt/PTEN/mTOR pathway: A fruitful target for inducing cell death in rheumatoid arthritis?Future Med. Chem.2015791137114710.4155/fmc.15.5526132523
     [Google Scholar]
  69. PerlA. Metabolic control of immune system activation in rheumatic diseases.Arthr. Rheumatol.201769122259227010.1002/art.4022328841779
     [Google Scholar]
  70. LaplanteM. SabatiniD.M. mTOR signaling in growth control and disease.Cell.2012149227429310.1016/j.cell.2012.03.01722500797
     [Google Scholar]
  71. HessJ. AngelP. Schorpp-KistnerM. AP-1 subunits: Quarrel and harmony among siblings.J. Cell Sci.2004117255965597310.1242/jcs.0158915564374
     [Google Scholar]
  72. ShaulianE. KarinM. AP-1 as a regulator of cell life and death.Nat. Cell Biol.200245E131E13610.1038/ncb0502‑e13111988758
     [Google Scholar]
  73. ChenY.H. WuK.H. WuH.P. Unraveling the complexities of toll- like receptors: From molecular mechanisms to clinical applications.Int. J. Mol. Sci.2024259503710.3390/ijms2509503738732254
     [Google Scholar]
  74. WadeW.F. Pattern recognition receptors and the innate immune network.Molecular medical microbiology.2nd EdCambridge, USAcademic Press2015144947410.1016/B978‑0‑12‑397169‑2.00026‑3
     [Google Scholar]
  75. WangS. LvJ. MengS. TangJ. NieL. Recent advances in nanotheranostics for treat-to-target of rheumatoid arthritis.Adv. Healthc. Mater.202096190154110.1002/adhm.20190154132031759
     [Google Scholar]
  76. FujimotoM. NakaT. Regulation of cytokine signaling by SOCS family molecules.Trends Immunol.2003241265966610.1016/j.it.2003.10.00814644140
     [Google Scholar]
  77. IsomäkiP. AlanäräT. IsohanniP. LagerstedtA. KorpelaM. MoilanenT. VisakorpiT. SilvennoinenO. The expression of SOCS is altered in rheumatoid arthritis.Rheumatology (Oxford)200746101538154610.1093/rheumatology/kem19817726036
     [Google Scholar]
  78. MuN. GuJ. HuangT. ZhangC. ShuZ. LiM. HaoQ. LiW. ZhangW. ZhaoJ. ZhangY. HuangL. WangS. JinX. XueX. ZhangW. ZhangY. A novel NF-κB/YY1/microRNA-10a regulatory circuit in fibroblast-like synoviocytes regulates inflammation in rheumatoid arthritis.Sci. Rep.2016612005910.1038/srep2005926821827
     [Google Scholar]
  79. LinJ. TangJ. LinJ. HeY. YuZ. JiangR. YangB. OuQ. YY1 regulation by miR-124-3p promotes Th17 cell pathogenicity through interaction with T-bet in rheumatoid arthritis.JCI Insight2021622e14998510.1172/jci.insight.14998534806650
     [Google Scholar]
  80. KatohM. KatohM. STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review).Int. J. Mol. Med.200719227327810.3892/ijmm.19.2.27317203201
     [Google Scholar]
  81. GrovesA.K. FeketeD.M. Shaping sound in space: The regulation of inner ear patterning.Development2012139224525710.1242/dev.06707422186725
     [Google Scholar]
  82. SigurdssonS. PadyukovL. KurreemanF.A.S. LiljedahlU. WimanA.C. AlfredssonL. ToesR. RönnelidJ. KlareskogL. HuizingaT.W.J. AlmG. SyvänenA.C. RönnblomL. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis.Arthritis Rheum.20075672202221010.1002/art.2270417599733
     [Google Scholar]
  83. SweeneyS.E. MoL. FiresteinG.S. Antiviral gene expression in rheumatoid arthritis: Role of IKKϵ and interferon regulatory factor 3.Arthritis Rheum.200756374375210.1002/art.2242117328045
     [Google Scholar]
  84. MattaB. SongS. LiD. BarnesB.J. Interferon regulatory factor signaling in autoimmune disease.Cytokine201798152610.1016/j.cyto.2017.02.00628283223
     [Google Scholar]
  85. EamesH.L. CorbinA.L. UdalovaI.A. Interferon regulatory factor 5 in human autoimmunity and murine models of autoimmune disease.Transl. Res.2016167116718210.1016/j.trsl.2015.06.01826207886
     [Google Scholar]
  86. Vila-del SolV. PunzónC. FresnoM. IFN-γ-induced TNF-α expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages.J. Immunol.200818174461447010.4049/jimmunol.181.7.446118802049
     [Google Scholar]
  87. BalendranT. LimK. HamiltonJ.A. AchuthanA.A. Targeting transcription factors for therapeutic benefit in rheumatoid arthritis.Front. Immunol.202314119693110.3389/fimmu.2023.119693137457726
     [Google Scholar]
  88. ThompsonC.D. MattaB. BarnesB.J. Therapeutic targeting of IRFs: Pathway-dependence or structure-based?Front. Immunol.20189262210.3389/fimmu.2018.0262230515152
     [Google Scholar]
  89. OkamotoH. CujecT.P. YamanakaH. KamataniN. Molecular aspects of rheumatoid arthritis: Role of transcription factors.FEBS J.2008275184463447010.1111/j.1742‑4658.2008.06582.x18662303
     [Google Scholar]
  90. BoissierM.C. Cell and cytokine imbalances in rheumatoid synovitis.Joint Bone Spine201178323023410.1016/j.jbspin.2010.08.01720961791
     [Google Scholar]
  91. RooneyM. CondellD. QuinlanW. DalyL. WhelanA. FeigheryC. BresnihanB. Analysis of the histologic variation of synovitis in rheumatoid arthritis.Arthritis Rheum.198831895696310.1002/art.17803108032457377
     [Google Scholar]
  92. KaneyamaK. SegamiN. NishimuraM. SuzukiT. SatoJ. Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders.Br. J. Oral Maxillofac. Surg.200240541842310.1016/S0266‑4356(02)00215‑212379189
     [Google Scholar]
  93. IsomäkiP. PunnonenJ. Pro- and anti-inflammatory cytokines in rheumatoid arthritis.Ann. Med.199729649950710.3109/078538997090074749562516
     [Google Scholar]
  94. MaedaK. KobayashiY. UdagawaN. UeharaS. IshiharaA. MizoguchiT. KikuchiY. TakadaI. KatoS. KaniS. NishitaM. MarumoK. MartinT.J. MinamiY. TakahashiN. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis.Nat. Med.201218340541210.1038/nm.265322344299
     [Google Scholar]
  95. GranetC. MaslinskiW. MiossecP. Increased AP-1 and NF-κB activation and recruitment with the combination of the proinflammatory cytokines IL-1β, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes.Arthritis Res. Ther.200463R190R19810.1186/ar115915142264
     [Google Scholar]
  96. MalemudC. Negative regulators of JAK/STAT signaling in rheumatoid arthritis and osteoarthritis.Int. J. Mol. Sci.201718348410.3390/ijms1803048428245561
     [Google Scholar]
  97. SenoltL. Emerging therapies in rheumatoid arthritis: Focus on monoclonal antibodies.F1000 Res.20198154910.12688/f1000research.18688.131508202
     [Google Scholar]
  98. BossallerL. RotheA. Monoclonal antibody treatments for rheumatoid arthritis.Expert Opin. Biol. Ther.20131391257127210.1517/14712598.2013.81123023789825
     [Google Scholar]
  99. StrietholtS. MaurerB. PetersM.A. PapT. GayS. Epigenetic modifications in rheumatoid arthritis.Arthritis Res. Ther.200810521910.1186/ar250018947370
     [Google Scholar]
  100. van der KraanP.M. The changing role of TGFβ in healthy, ageing and osteoarthritic joints.Nat. Rev. Rheumatol.201713315516310.1038/nrrheum.2016.21928148919
     [Google Scholar]
  101. SuN. JinM. ChenL. Role of FGF/FGFR signaling in skeletal development and homeostasis: Learning from mouse models.Bone Res.2014211400310.1038/boneres.2014.326273516
     [Google Scholar]
  102. SobahM.L. LiongueC. WardA.C. SOCS proteins in immunity, inflammatory diseases, and immune-related cancer.Front. Med. (Lausanne)2021872798710.3389/fmed.2021.72798734604264
     [Google Scholar]
  103. KraanVan der P. The changing role of TGFẞ in healthy, ageing and osteoarthritic joints.Nat Rev Rheumatol2017133155-163
     [Google Scholar]
/content/journals/crr/10.2174/0115733971346656250403051144
Loading
The Role of Synovitis and Latent Transcription Factors in the Pathogenesis of Rheumatoid Arthritis
Curr. Rheumatol. Rev. 22, 48 (2026); https://doi.org/10.2174/0115733971346656250403051144
/content/journals/crr/10.2174/0115733971346656250403051144
/content/journals/crr/10.2174/0115733971346656250403051144
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): NF-κB; p38 MAPK; Rheumatoid arthritis; synovitis, joint damage; transcription factors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test